Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 8Phase 1 3Phase 1/2 2

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Lung Neoplasms 2Small Cell Lung Carcinoma 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × amrubicin × Clear all
NCT00915083 2019-11-01

A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

Celgene

Phase 1 Completed
24 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00890955 2015-12-23

Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies

Hoosier Cancer Research Network

Phase 1 Completed
36 enrolled
Thoracic

Lung Neoplasms

NCT00132054 2013-05-30

Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡